IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services primarily to the life sciences industry across various global regions. Its revenue is derived from three main segments: Technology & Analytics Solutions (approximately 50%), Research & Development Solutions (around 30%), and Contract Sales & Medical Solutions (about 20%). The company's customers include pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. Factors supporting its endurance include a growing demand for data-driven insights in healthcare and a strong reputation in clinical research, while potential limitations could stem from regulatory changes and competition in the analytics space.
—
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services primarily to the life sciences industry across various global regions. Its revenue is derived from three main segments: Technology & Analytics Solutions (approximately 50%), Research & Development Solutions (around 30%), and Contract Sales & Medical Solutions (about 20%). The company's customers include pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. Factors supporting its endurance include a growing demand for data-driven insights in healthcare and a strong reputation in clinical research, while potential limitations could stem from regulatory changes and competition in the analytics space.
—
Daily adjusted close
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services primarily to the life sciences industry across various global regions. Its revenue is derived from three main segments: Technology & Analytics Solutions (approximately 50%), Research & Development Solutions (around 30%), and Contract Sales & Medical Solutions (about 20%). The company's customers include pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. Factors supporting its endurance include a growing demand for data-driven insights in healthcare and a strong reputation in clinical research, while potential limitations could stem from regulatory changes and competition in the analytics space.